Aerobic Exercise and Metabolic Syndrome: The Role of Sympathetic Activity and the Redox System
Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide. The aim of this s...
Saved in:
Published in | Diabetes, metabolic syndrome and obesity Vol. 13; pp. 2433 - 2442 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New Zealand
Dove Medical Press Limited
01.01.2020
Dove Dove Medical Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide.
The aim of this study was to analyze the beneficial effects of aerobic exercise without dietary changes, in a cohort of MetS subjects, focusing on the role of sympathetic and orexinergic activity. Several blood parameters linked to MetS ROS production, heart rate, galvanic skin response, d-ROM test, and Orexin A serum levels were evaluated in ten males with MetS (BMI 30-34.9) before and after a period of 6 months of aerobic exercise compared to ten healthy subjects.
Ten male subjects (aged 54 ± 4.16) with MetS (MetS group) and ten healthy males (aged 49.7 ± 2.79, Healthy group) were told about the study protocol and possible risks, signed the informed consent, and voluntarily participated in the study. Several blood parameters were evaluated in the two tested groups and were re-evaluated in the MetS group after 6 months of training (MetS6M group). The training protocol consisted of more than 30 min/day of walking (average speed of 4.5 km/h) and 3 days/week of aerobic activities (jogging under heart rate control - 120-140 bpm for 45 min).
The results showed that exercise induced a significant increase in GSR and plasma Orexin A but no significant increase in d-ROM values. Significant decreases in the serum ALT enzyme, triglycerides, and total cholesterol were found, while the HDL levels were significantly higher. Finally, a significant reduction of BMI and resting HR were reported.
The results of this study confirm that physical activity is associated with sympathetic activation, having a pivotal role against adverse effects linked to MetS. Moreover, this study demonstrates that, in patients with MetS, Orexin A is involved in hormonal adaptations to exercise. |
---|---|
AbstractList | Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide.
The aim of this study was to analyze the beneficial effects of aerobic exercise without dietary changes, in a cohort of MetS subjects, focusing on the role of sympathetic and orexinergic activity. Several blood parameters linked to MetS ROS production, heart rate, galvanic skin response, d-ROM test, and Orexin A serum levels were evaluated in ten males with MetS (BMI 30-34.9) before and after a period of 6 months of aerobic exercise compared to ten healthy subjects.
Ten male subjects (aged 54 ± 4.16) with MetS (MetS group) and ten healthy males (aged 49.7 ± 2.79, Healthy group) were told about the study protocol and possible risks, signed the informed consent, and voluntarily participated in the study. Several blood parameters were evaluated in the two tested groups and were re-evaluated in the MetS group after 6 months of training (MetS6M group). The training protocol consisted of more than 30 min/day of walking (average speed of 4.5 km/h) and 3 days/week of aerobic activities (jogging under heart rate control - 120-140 bpm for 45 min).
The results showed that exercise induced a significant increase in GSR and plasma Orexin A but no significant increase in d-ROM values. Significant decreases in the serum ALT enzyme, triglycerides, and total cholesterol were found, while the HDL levels were significantly higher. Finally, a significant reduction of BMI and resting HR were reported.
The results of this study confirm that physical activity is associated with sympathetic activation, having a pivotal role against adverse effects linked to MetS. Moreover, this study demonstrates that, in patients with MetS, Orexin A is involved in hormonal adaptations to exercise. Vincenzo Monda,1 Francesco Sessa,2 Maria Ruberto,3 Marco Carotenuto,4 Gabriella Marsala,5 Marcellino Monda,1 Maria Teresa Cambria,6 Marinella Astuto,7 Alfio Distefano,6 Giovanni Messina2 1Department of Experimental Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Caserta 81100, Italy; 2Department of Clinical and Experimental Medicine, University of Foggia, Foggia 71121, Italy; 3CDR Santa Maria del Pozzo, Naples 80049, Italy; 4Clinic of Child and Adolescent Neuropsychiatry, Department of Mental Health, Physical and Preventive Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Caserta 81100, Italy; 5Struttura Complessa di Farmacia, Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Foggia, Foggia 71121, Italy; 6Section of Medical Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania 95123, Italy; 7Azienda Ospedaliera "Policlinico Vittorio Emanuele", U.O. di Anestesia e Terapia Intensiva, Catania 95123, ItalyCorrespondence: Francesco SessaDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia 71122, ItalyTel +39 0881 736926Email francesco.sessa@unifg.itBackground: Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide.Aim: The aim of this study was to analyze the beneficial effects of aerobic exercise without dietary changes, in a cohort of MetS subjects, focusing on the role of sympathetic and orexinergic activity. Several blood parameters linked to MetS ROS production, heart rate, galvanic skin response, d-ROM test, and Orexin A serum levels were evaluated in ten males with MetS (BMI 30- 34.9) before and after a period of 6 months of aerobic exercise compared to ten healthy subjects.Methods: Ten male subjects (aged 54 ± 4.16) with MetS (MetS group) and ten healthy males (aged 49.7 ± 2.79, Healthy group) were told about the study protocol and possible risks, signed the informed consent, and voluntarily participated in the study. Several blood parameters were evaluated in the two tested groups and were re-evaluated in the MetS group after 6 months of training (MetS6M group). The training protocol consisted of more than 30 min/day of walking (average speed of 4.5 km/h) and 3 days/week of aerobic activities (jogging under heart rate control - 120- 140 bpm for 45 min).Results: The results showed that exercise induced a significant increase in GSR and plasma Orexin A but no significant increase in d-ROM values. Significant decreases in the serum ALT enzyme, triglycerides, and total cholesterol were found, while the HDL levels were significantly higher. Finally, a significant reduction of BMI and resting HR were reported.Conclusion: The results of this study confirm that physical activity is associated with sympathetic activation, having a pivotal role against adverse effects linked to MetS. Moreover, this study demonstrates that, in patients with MetS, Orexin A is involved in hormonal adaptations to exercise.Keywords: metabolic syndrome, MetS, Orexin A, body mass index, BMI, heart rate, HR, cholesterol, physical activity Background: Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide. Aim: The aim of this study was to analyze the beneficial effects of aerobic exercise without dietary changes, in a cohort of MetS subjects, focusing on the role of sympathetic and orexinergic activity. Several blood parameters linked to MetS ROS production, heart rate, galvanic skin response, d-ROM test, and Orexin A serum levels were evaluated in ten males with MetS (BMI 30-34.9) before and after a period of 6 months of aerobic exercise compared to ten healthy subjects. Methods: Ten male subjects (aged 54 [+ or -] 4.16) with MetS (MetS group) and ten healthy males (aged 49.7 [+ or -] 2.79, Healthy group) were told about the study protocol and possible risks, signed the informed consent, and voluntarily participated in the study. Several blood parameters were evaluated in the two tested groups and were re-evaluated in the MetS group after 6 months of training (MetS6M group). The training protocol consisted of more than 30 min/day of walking (average speed of 4.5 km/h) and 3 days/week of aerobic activities (jogging under heart rate control - 120-140 bpm for 45 min). Results: The results showed that exercise induced a significant increase in GSR and plasma Orexin A but no significant increase in d-ROM values. Significant decreases in the serum ALT enzyme, triglycerides, and total cholesterol were found, while the HDL levels were significantly higher. Finally, a significant reduction of BMI and resting HR were reported. Conclusion: The results of this study confirm that physical activity is associated with sympathetic activation, having a pivotal role against adverse effects linked to MetS. Moreover, this study demonstrates that, in patients with MetS, Orexin A is involved in hormonal adaptations to exercise. Keywords: metabolic syndrome, MetS, Orexin A, body mass index, BMI, heart rate, HR, cholesterol, physical activity Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide.BACKGROUNDAerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide.The aim of this study was to analyze the beneficial effects of aerobic exercise without dietary changes, in a cohort of MetS subjects, focusing on the role of sympathetic and orexinergic activity. Several blood parameters linked to MetS ROS production, heart rate, galvanic skin response, d-ROM test, and Orexin A serum levels were evaluated in ten males with MetS (BMI 30-34.9) before and after a period of 6 months of aerobic exercise compared to ten healthy subjects.AIMThe aim of this study was to analyze the beneficial effects of aerobic exercise without dietary changes, in a cohort of MetS subjects, focusing on the role of sympathetic and orexinergic activity. Several blood parameters linked to MetS ROS production, heart rate, galvanic skin response, d-ROM test, and Orexin A serum levels were evaluated in ten males with MetS (BMI 30-34.9) before and after a period of 6 months of aerobic exercise compared to ten healthy subjects.Ten male subjects (aged 54 ± 4.16) with MetS (MetS group) and ten healthy males (aged 49.7 ± 2.79, Healthy group) were told about the study protocol and possible risks, signed the informed consent, and voluntarily participated in the study. Several blood parameters were evaluated in the two tested groups and were re-evaluated in the MetS group after 6 months of training (MetS6M group). The training protocol consisted of more than 30 min/day of walking (average speed of 4.5 km/h) and 3 days/week of aerobic activities (jogging under heart rate control - 120-140 bpm for 45 min).METHODSTen male subjects (aged 54 ± 4.16) with MetS (MetS group) and ten healthy males (aged 49.7 ± 2.79, Healthy group) were told about the study protocol and possible risks, signed the informed consent, and voluntarily participated in the study. Several blood parameters were evaluated in the two tested groups and were re-evaluated in the MetS group after 6 months of training (MetS6M group). The training protocol consisted of more than 30 min/day of walking (average speed of 4.5 km/h) and 3 days/week of aerobic activities (jogging under heart rate control - 120-140 bpm for 45 min).The results showed that exercise induced a significant increase in GSR and plasma Orexin A but no significant increase in d-ROM values. Significant decreases in the serum ALT enzyme, triglycerides, and total cholesterol were found, while the HDL levels were significantly higher. Finally, a significant reduction of BMI and resting HR were reported.RESULTSThe results showed that exercise induced a significant increase in GSR and plasma Orexin A but no significant increase in d-ROM values. Significant decreases in the serum ALT enzyme, triglycerides, and total cholesterol were found, while the HDL levels were significantly higher. Finally, a significant reduction of BMI and resting HR were reported.The results of this study confirm that physical activity is associated with sympathetic activation, having a pivotal role against adverse effects linked to MetS. Moreover, this study demonstrates that, in patients with MetS, Orexin A is involved in hormonal adaptations to exercise.CONCLUSIONThe results of this study confirm that physical activity is associated with sympathetic activation, having a pivotal role against adverse effects linked to MetS. Moreover, this study demonstrates that, in patients with MetS, Orexin A is involved in hormonal adaptations to exercise. |
Audience | Academic |
Author | Monda, Marcellino Astuto, Marinella Ruberto, Maria Sessa, Francesco Distefano, Alfio Monda, Vincenzo Carotenuto, Marco Marsala, Gabriella Cambria, Maria Teresa Messina, Giovanni |
Author_xml | – sequence: 1 givenname: Vincenzo surname: Monda fullname: Monda, Vincenzo – sequence: 2 givenname: Francesco orcidid: 0000-0003-0357-8791 surname: Sessa fullname: Sessa, Francesco – sequence: 3 givenname: Maria surname: Ruberto fullname: Ruberto, Maria – sequence: 4 givenname: Marco orcidid: 0000-0002-8136-7597 surname: Carotenuto fullname: Carotenuto, Marco – sequence: 5 givenname: Gabriella orcidid: 0000-0003-0981-4134 surname: Marsala fullname: Marsala, Gabriella – sequence: 6 givenname: Marcellino surname: Monda fullname: Monda, Marcellino – sequence: 7 givenname: Maria Teresa surname: Cambria fullname: Cambria, Maria Teresa – sequence: 8 givenname: Marinella orcidid: 0000-0002-9365-1309 surname: Astuto fullname: Astuto, Marinella – sequence: 9 givenname: Alfio surname: Distefano fullname: Distefano, Alfio – sequence: 10 givenname: Giovanni surname: Messina fullname: Messina, Giovanni |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32753926$$D View this record in MEDLINE/PubMed |
BookMark | eNptkt1r2zAUxc3oWLuub3sehsHYw5JZX5bdh0Houq3QUli614lr6TpRsa1MUkr7309u0pGMSg8SV79zuJLO6-xgcANm2VtSTCnh8vPXq_n1dE6FLCv5IjsiRFYTWRTyYGd_mJ2EcFuMQxac0lfZIaNSsJqWR9nvGXrXWJ2f36PXNmAOg8mvMELjulSePwzGux5P85sl5j9dh7lrU7VfQVxiTMRMR3tn48OjMI4QGnefkBCxf5O9bKELeLJdj7Nf385vzn5MLq-_X5zNLie6JDxOGCGNLIhk2jBREKC1bpigRpZatJqZGiSShBquGQNRCl0LrJG1Ak1jsGHH2cXG1zi4VStve_APyoFVjwXnFwp86rZDVZFaQsWhYqzigpY1QFlVQIgGUzW8Sl5fNl6rddOj0ThED92e6f7JYJdq4e6UZILXhCeDj1sD7_6sMUTV26Cx62BAtw6KclaU6cP4iL7foAtIrdmhdclRj7ialYzWRXoUkajpM1SaBnurUyJam-p7gg87giVCF5fBdeto3RD2wXe7d_13yaeAJIBuAO1dCB5bpW2E0Se1YDtFCjUGUY1BVNsgJtGn_0RPvs_ifwHghNvw |
CitedBy_id | crossref_primary_10_1002_wsbm_1536 crossref_primary_10_1016_j_celrep_2022_111497 crossref_primary_10_3390_ijerph19095145 crossref_primary_10_1097_MD_0000000000034206 crossref_primary_10_1097_YIC_0000000000000552 crossref_primary_10_3390_nu17061095 crossref_primary_10_1007_s40519_022_01434_2 crossref_primary_10_1016_j_yfrne_2022_100993 crossref_primary_10_3390_metabo10110455 crossref_primary_10_7759_cureus_34009 crossref_primary_10_3390_ijms251910742 crossref_primary_10_1016_j_bbr_2023_114791 |
Cites_doi | 10.3390/antiox8120643 10.2165/00007256-200636040-00004 10.3389/fphys.2018.00261 10.1161/01.CIR.0000075572.40158.77 10.3389/fphys.2017.00773 10.1155/2016/3565127 10.1152/ajpregu.1999.277.6.R1780 10.1152/physrev.00018.2001 10.1113/expphysiol.2009.050526 10.1016/j.jshs.2016.04.001 10.1046/j.1365-2362.2003.01227.x 10.1016/j.nbd.2014.08.025 10.1155/2014/943162 10.1515/jbcpp-2015-0133 10.1016/j.autneu.2012.05.003 10.6064/2012/205027 10.18632/oncotarget.24729 10.1111/j.1467-789X.2012.00992.x 10.1097/AUD.0000000000000305 10.3389/fneur.2017.00188 10.1152/ajpregu.00208.2003 10.3389/fphys.2018.00259 10.3389/fphys.2017.00085 10.1016/j.mehy.2008.12.037 10.3727/105221617X15124844266408 10.1146/annurev.arplant.55.031903.141701 10.1371/journal.pone.0032361 10.1161/CIRCULATIONAHA.108.191394 10.1152/ajpheart.00703.2016 10.1111/obr.12229 10.1016/j.cbi.2017.12.024 10.1016/0026-0495(94)90277-1 10.1089/ars.2011.3976 10.1155/2016/7239639 10.18632/aging.101386 10.1155/2017/3831972 10.1007/s00424-002-0918-6 10.1124/pr.109.001321 10.1155/2014/131024 10.1007/s12035-017-0865-z 10.1249/MSS.0000000000001122 10.1242/dmm.001180 10.1016/j.jnutbio.2015.08.024 10.1164/rccm.201204-0596PP 10.1007/s40519-014-0107-6 10.1161/01.CIR.0000111245.75752.C6 10.1016/j.bbadis.2013.06.007 10.1007/s11332-018-0464-z 10.1098/rsfs.2014.0040 10.2741/4736 10.3389/fphys.2018.00982 10.1016/j.molmet.2015.07.003 10.1016/j.numecd.2006.07.005 |
ContentType | Journal Article |
Copyright | 2020 Monda et al. COPYRIGHT 2020 Dove Medical Press Limited 2020 Monda et al. 2020 Monda et al. |
Copyright_xml | – notice: 2020 Monda et al. – notice: COPYRIGHT 2020 Dove Medical Press Limited – notice: 2020 Monda et al. 2020 Monda et al. |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.2147/DMSO.S257687 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Monda et al |
EISSN | 1178-7007 |
EndPage | 2442 |
ExternalDocumentID | oai_doaj_org_article_8197a84a833845269aa688a11cad8b48 PMC7354914 A632900175 32753926 10_2147_DMSO_S257687 |
Genre | Journal Article |
GroupedDBID | --- 0YH 29F 2WC 53G 5VS 7RV 8C1 8FI 8FJ 8G5 AAYXX ABUWG ACGFO ADBBV ADRAZ AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BKEYQ BPHCQ BVXVI C1A CCPQU CITATION DIK DWQXO E3Z EBD EBS EJD FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HYE IAO IHR IHW IPNFZ ITC KQ8 M2O M48 M~E NAPCQ O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RIG RNS RPM TDBHL TR2 UKHRP VDV NPM PMFND 7X8 PJZUB PPXIY 5PM PUEGO |
ID | FETCH-LOGICAL-c614t-311b70173cd3501a29cb352d76c5fc3d9a7e1c61d4c33a565c95e9e3f5edbdeb3 |
IEDL.DBID | M48 |
ISSN | 1178-7007 |
IngestDate | Wed Aug 27 01:31:28 EDT 2025 Thu Aug 21 14:11:05 EDT 2025 Tue Aug 05 10:39:21 EDT 2025 Tue Jun 17 20:58:10 EDT 2025 Tue Jun 10 20:42:57 EDT 2025 Thu May 22 21:04:51 EDT 2025 Thu Jan 02 22:54:36 EST 2025 Tue Jul 01 01:45:16 EDT 2025 Thu Apr 24 22:59:42 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | metabolic syndrome heart rate MetS Orexin A body mass index cholesterol HR BMI physical activity |
Language | English |
License | http://creativecommons.org/licenses/by-nc/3.0 2020 Monda et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c614t-311b70173cd3501a29cb352d76c5fc3d9a7e1c61d4c33a565c95e9e3f5edbdeb3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-9365-1309 0000-0003-0357-8791 0000-0002-8136-7597 0000-0003-0981-4134 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.2147/DMSO.S257687 |
PMID | 32753926 |
PQID | 2430668744 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_8197a84a833845269aa688a11cad8b48 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7354914 proquest_miscellaneous_2430668744 gale_infotracmisc_A632900175 gale_infotracacademiconefile_A632900175 gale_healthsolutions_A632900175 pubmed_primary_32753926 crossref_citationtrail_10_2147_DMSO_S257687 crossref_primary_10_2147_DMSO_S257687 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2020-01-01 |
PublicationDateYYYYMMDD | 2020-01-01 |
PublicationDate_xml | – month: 01 year: 2020 text: 2020-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | New Zealand |
PublicationPlace_xml | – name: New Zealand |
PublicationTitle | Diabetes, metabolic syndrome and obesity |
PublicationTitleAlternate | Diabetes Metab Syndr Obes |
PublicationYear | 2020 |
Publisher | Dove Medical Press Limited Dove Dove Medical Press |
Publisher_xml | – name: Dove Medical Press Limited – name: Dove – name: Dove Medical Press |
References | Holvoet (ref28) 2012; 2012 Radák (ref57) 2002; 445 Sessa (ref12) 2018; 10 Davalli (ref17) 2016; 2016 Silverman (ref30) 2014; 4 Apel (ref58) 2004; 55 Monda (ref20) 2017; 8 Sperandeo (ref48) 2018; 34 Van Der Windt (ref11) 2018; 18 Chieffi (ref7) 2017; 8 Perez-Leighton (ref45) 2014; 1842 Sessa (ref6) 2018; 14 Williams (ref49) 1994; 43 Grundy (ref37) 2006 Monda (ref24) 2017; 2017 O’Neill (ref38) 2015; 16 Finaud (ref62) 2006; 36 Vestbo (ref52) 2013; 187 Rizzo (ref61) 2016; 7 Kaur (ref2) 2014; 2014 Cazzola (ref60) 2003; 33 Monda (ref53) 2014; 2014 Sallam (ref54) 2016; 2016 Dongiovanni (ref51) 2016; 29 Monda (ref43) 2019; 33 Salerno (ref47) 2019; 24 Simioni (ref16) 2018; 9 Hart (ref27) 2017; 312 Couillard (ref50) 2007 ref34 Polito (ref46) 2018; 9 ref33 Messina (ref18) 2018; 9 Monda (ref25) 2018; 55 Marra (ref23) 2017; 33 Shirasaka (ref26) 1999; 277 Powers (ref19) 2010; 95 Navarro (ref56) 2004; 286 Obici (ref5) 2015; 4 Jackson (ref59) 2011; 15 Chieffi (ref36) 2017; 8 Normandin (ref9) 2017; 49 Tsujino (ref44) 2009; 61 Huang (ref32) 2014; 72 Messina (ref13) 2012; 169 Donini (ref10) 2014; 19 Mackersie (ref31) 2016; 37 Byrne (ref4) 2018; 362 Wiklund (ref8) 2016; 5 Phull (ref15) 2018; 281 Huang (ref3) 2009; 2 Messina (ref22) 2016; 27 Messina (ref42) 2018; 9 Grundy (ref1) 2004; 109 Ritchie (ref39) 2007; 17 Li (ref55) 2009; 72 Messina (ref21) 2017; 33 Chaput (ref29) 2012; 13 Valenzano (ref35) 2019; 8 Thompson (ref40) 2003; 107 Steinberger (ref41) 2009; 119 Dröge (ref14) 2002; 82 |
References_xml | – volume: 8 start-page: 643 year: 2019 ident: ref35 publication-title: Antioxidants doi: 10.3390/antiox8120643 – volume: 36 start-page: 327 year: 2006 ident: ref62 publication-title: Sports Med doi: 10.2165/00007256-200636040-00004 – volume: 9 year: 2018 ident: ref42 publication-title: Front Physiol doi: 10.3389/fphys.2018.00261 – volume: 107 start-page: 3109 year: 2003 ident: ref40 publication-title: Circulation doi: 10.1161/01.CIR.0000075572.40158.77 – volume: 8 year: 2017 ident: ref20 publication-title: Front Physiol doi: 10.3389/fphys.2017.00773 – volume: 33 start-page: 645 year: 2017 ident: ref21 publication-title: Acta Medica Mediterr – volume: 2016 start-page: 1 year: 2016 ident: ref17 publication-title: Oxid Med Cell Longev doi: 10.1155/2016/3565127 – volume: 362 year: 2018 ident: ref4 publication-title: BMJ – volume: 277 start-page: R1780 year: 1999 ident: ref26 publication-title: Am J Physiol Regul Integr Comp Physiol doi: 10.1152/ajpregu.1999.277.6.R1780 – volume: 82 start-page: 47 year: 2002 ident: ref14 publication-title: Physiol Rev doi: 10.1152/physrev.00018.2001 – volume: 95 start-page: 1 year: 2010 ident: ref19 publication-title: Exp Physiol doi: 10.1113/expphysiol.2009.050526 – volume: 33 start-page: 587 year: 2019 ident: ref43 publication-title: J Biol Regul Homeost Agents – volume: 5 start-page: 151 year: 2016 ident: ref8 publication-title: J Sport Health Sci doi: 10.1016/j.jshs.2016.04.001 – volume: 33 start-page: 924 year: 2003 ident: ref60 publication-title: Eur J Clin Invest doi: 10.1046/j.1365-2362.2003.01227.x – volume: 72 start-page: 3 year: 2014 ident: ref32 publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2014.08.025 – volume: 2014 start-page: 1 year: 2014 ident: ref2 publication-title: Cardiol Res Pract doi: 10.1155/2014/943162 – volume: 27 start-page: 611 year: 2016 ident: ref22 publication-title: J Basic Clin Physiol Pharmacol doi: 10.1515/jbcpp-2015-0133 – volume: 169 start-page: 102 year: 2012 ident: ref13 publication-title: Auton Neurosci Basic Clin doi: 10.1016/j.autneu.2012.05.003 – ident: ref34 – volume: 2012 start-page: 1 year: 2012 ident: ref28 publication-title: Scientifica (Cairo) doi: 10.6064/2012/205027 – volume: 9 start-page: 17181 year: 2018 ident: ref16 publication-title: Oncotarget doi: 10.18632/oncotarget.24729 – volume: 13 start-page: 681 year: 2012 ident: ref29 publication-title: Obes Rev doi: 10.1111/j.1467-789X.2012.00992.x – volume: 37 start-page: 118S year: 2016 ident: ref31 publication-title: Ear Hear doi: 10.1097/AUD.0000000000000305 – volume: 8 year: 2017 ident: ref7 publication-title: Front Neurol doi: 10.3389/fneur.2017.00188 – volume: 286 start-page: R505 year: 2004 ident: ref56 publication-title: Am J Physiol Integr Comp Physiol doi: 10.1152/ajpregu.00208.2003 – volume: 9 year: 2018 ident: ref18 publication-title: Front Physiol doi: 10.3389/fphys.2018.00259 – volume: 8 year: 2017 ident: ref36 publication-title: Front Physiol doi: 10.3389/fphys.2017.00085 – year: 2007 ident: ref50 publication-title: Arterioscler Thromb Vasc Biol – volume: 72 start-page: 527 year: 2009 ident: ref55 publication-title: Med Hypotheses doi: 10.1016/j.mehy.2008.12.037 – volume: 18 start-page: 89 year: 2018 ident: ref11 publication-title: Gene Expr doi: 10.3727/105221617X15124844266408 – ident: ref33 – volume: 55 start-page: 373 year: 2004 ident: ref58 publication-title: Annu Rev Plant Biol doi: 10.1146/annurev.arplant.55.031903.141701 – volume: 7 start-page: e32361 year: 2016 ident: ref61 publication-title: PLoS One doi: 10.1371/journal.pone.0032361 – volume: 119 start-page: 628 year: 2009 ident: ref41 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.108.191394 – volume: 312 start-page: H1031 year: 2017 ident: ref27 publication-title: Am J Physiol Heart Circ Physiol doi: 10.1152/ajpheart.00703.2016 – volume: 16 start-page: 1 year: 2015 ident: ref38 publication-title: Obes Rev doi: 10.1111/obr.12229 – volume: 281 start-page: 121 year: 2018 ident: ref15 publication-title: Chem Biol Interact doi: 10.1016/j.cbi.2017.12.024 – volume: 33 start-page: 1225 year: 2017 ident: ref23 publication-title: Acta Medica Mediterr – volume: 43 start-page: 917 year: 1994 ident: ref49 publication-title: Metabolism doi: 10.1016/0026-0495(94)90277-1 – volume: 15 start-page: 2477 year: 2011 ident: ref59 publication-title: Antioxid Redox Signal doi: 10.1089/ars.2011.3976 – volume: 2016 start-page: 1 year: 2016 ident: ref54 publication-title: Oxid Med Cell Longev doi: 10.1155/2016/7239639 – volume: 10 start-page: 166 year: 2018 ident: ref12 publication-title: Aging (Albany NY) doi: 10.18632/aging.101386 – volume: 2017 start-page: 1 year: 2017 ident: ref24 publication-title: Oxid Med Cell Longev doi: 10.1155/2017/3831972 – volume: 445 start-page: 273 year: 2002 ident: ref57 publication-title: Pflugers Arch doi: 10.1007/s00424-002-0918-6 – volume: 61 start-page: 162 year: 2009 ident: ref44 publication-title: Pharmacol Rev doi: 10.1124/pr.109.001321 – year: 2006 ident: ref37 publication-title: Curr Opin Cardiol – volume: 2014 year: 2014 ident: ref53 publication-title: Oxid Med Cell Longev doi: 10.1155/2014/131024 – volume: 55 start-page: 1 year: 2018 ident: ref25 publication-title: Mol Neurobiol doi: 10.1007/s12035-017-0865-z – volume: 49 start-page: 413 year: 2017 ident: ref9 publication-title: Med Sci Sports Exerc doi: 10.1249/MSS.0000000000001122 – volume: 2 start-page: 231 year: 2009 ident: ref3 publication-title: Dis Model Mech doi: 10.1242/dmm.001180 – volume: 29 start-page: 1 year: 2016 ident: ref51 publication-title: J Nutr Biochem doi: 10.1016/j.jnutbio.2015.08.024 – volume: 187 start-page: 347 year: 2013 ident: ref52 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201204-0596PP – volume: 19 start-page: 249 year: 2014 ident: ref10 publication-title: Eat Weight Disord doi: 10.1007/s40519-014-0107-6 – volume: 34 start-page: 349 year: 2018 ident: ref48 publication-title: Acta Medica Mediterr – volume: 109 start-page: 433 year: 2004 ident: ref1 publication-title: Circulation doi: 10.1161/01.CIR.0000111245.75752.C6 – volume: 1842 start-page: 440 year: 2014 ident: ref45 publication-title: Biochim Biophys Acta Mol Basis Dis doi: 10.1016/j.bbadis.2013.06.007 – volume: 14 start-page: 705 year: 2018 ident: ref6 publication-title: Sport Sci Health doi: 10.1007/s11332-018-0464-z – volume: 4 start-page: 20140040 year: 2014 ident: ref30 publication-title: Interface Focus doi: 10.1098/rsfs.2014.0040 – volume: 24 start-page: 564 year: 2019 ident: ref47 publication-title: Front Biosci doi: 10.2741/4736 – volume: 9 year: 2018 ident: ref46 publication-title: Front Physiol doi: 10.3389/fphys.2018.00982 – volume: 4 start-page: 692 year: 2015 ident: ref5 publication-title: Mol Metab doi: 10.1016/j.molmet.2015.07.003 – volume: 17 start-page: 319 year: 2007 ident: ref39 publication-title: Nutr Metab Cardiovasc Dis doi: 10.1016/j.numecd.2006.07.005 |
SSID | ssj0000070422 |
Score | 2.268805 |
Snippet | Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic... Background: Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with... Vincenzo Monda,1 Francesco Sessa,2 Maria Ruberto,3 Marco Carotenuto,4 Gabriella Marsala,5 Marcellino Monda,1 Maria Teresa Cambria,6 Marinella Astuto,7 Alfio... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 2433 |
SubjectTerms | Analysis body mass index (bmi) cholesterol Exercise Heart rate heart rate (hr) Medical research metabolic syndrome (mets) orexin a Original Research physical activity |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3faxQxEA7SB_FF_O1qrREUH2Tt7Sa7SXy71pYinIJnoU-GbDJLhetu6W3BP9-ZZHvcIuJLHzeZhWQyk5nZTb6PsbdNFXQwrcjbEEG1QeYGdJsT0ItsvZ8l4PnF1_rkVH45q862qL7oTFiCB06K28eIpZyWTmMtFemwnau1dkXhXdCNjNd8MeZtFVMp8VUEbpWYVXSu8Dmdeidanv1wse4_rmOqrSbxKML2_705b0Wn6cnJrVB0_IDdH3NIPk9jf8juQPeI3V2Mf8kfs59zIHQlz49GPiXuusAXMOCCr7B5OaIUfOJoJPx7vwLet9h6QfTEdKmRz30ilYgvDiQEof_NE7z5E3Z6fPTj8CQfeRRyj8F3wG22aBR6nvCBfiO60vgG866gal-1XgTjFBQoGqQXwmGG500FBkRbQWgCVttP2U7Xd_Cc8Vnta5hBBR4UYdEbXcngTA1BQNClz9iHG21aP4KME9fFymKxQbq3nxfLb3aZdJ-xdxvpywSu8Q-5A1qYjQxBYscGNBQ7Gor9n6Fk7DUtq033SzeObee1KA0F6ypj76MEuTYO2rvxhgJOnUCyJpK7E0l0ST_pfnNjOpa66BxbB_312pYSS7SaKAcy9iyZ0mZWosTS0ZR1xtTEyCbTnvZ0v84jIrgSWOYX8sVt6Oklu1fSN4X4mWmX7QxX1_AKE6-h2Ys-9gcg1Sh0 priority: 102 providerName: Directory of Open Access Journals |
Title | Aerobic Exercise and Metabolic Syndrome: The Role of Sympathetic Activity and the Redox System |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32753926 https://www.proquest.com/docview/2430668744 https://pubmed.ncbi.nlm.nih.gov/PMC7354914 https://doaj.org/article/8197a84a833845269aa688a11cad8b48 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3di9QwEB_uA8QX8dvquVZQfJCe2yZtUkFk79zzEPaUWxf26UqapCrstbrbg_O_dybpLldO8aXQZFqaZKYzk4_fD-BFmRpp8opFlXGg2pZHuZVVREAvvNJ66IHnJyfZ8Yx_mqfzLVizjXYduPprakd8UrPlYv_y1-_3aPDvaBtzzMUbc75q9lcuchbbsIs-SRCXwaQL9H0gLAjsyjOtyEjgvd8Ff-0FPf_kYPyv_6yveKv-TsorrunoNtzqYspw5JXgDmzZ-i7cmHSr5vfgbGQJbUmH445fKVS1CSe2RQVYYPG0Qy14G6LShKfNwoZNhaXnRFdMhxzDkfYkE-7BloSsaS5DD3d-H2ZH46-Hx1HHqxBpdMYt_nbjUqAlMm1oWVEluS4xDjMi02mlmcmVsDGKGq4ZUxjx6Ty1uWVVak1pMPt-ADt1U9tHEA4zndmhTa22grDpc5lyo_LMGmaNTHQAr9e9WegOdJy4LxYFJh_U98WHyfRzMfV9H8DLjfRPD7bxD7kDGpiNDEFku4Jm-a3oLK7AUEcoyZXEJNzxqCuVSaniWCsjSy4DeEbDWvjzphtDL0YZS3Jy3mkAr5wEKR9-tFbdiQVsOoFm9ST3epJoorpX_XytOgVV0b622jYXqyLhmLJlREEQwEOvSptWsQRTyTzJAhA9Jes1u19T__juEMIFw7Q_5o__28QncDOhCQQ3p7QHO-3ywj7FKKstB7AtD-MB7B6MT76cDtxcBV4_zrGMTOsPwwgpOQ |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Aerobic+Exercise+and+Metabolic+Syndrome%3A+The+Role+of+Sympathetic+Activity+and+the+Redox+System&rft.jtitle=Diabetes%2C+metabolic+syndrome+and+obesity&rft.au=Distefano%2C+Alfio&rft.au=Carotenuto%2C+Marco&rft.au=Cambria%2C+Maria+Teresa&rft.au=Astuto%2C+Marinella&rft.date=2020-01-01&rft.pub=Dove+Medical+Press+Limited&rft.issn=1178-7007&rft.eissn=1178-7007&rft.volume=13&rft.spage=2433&rft_id=info:doi/10.2147%2Fdmso.s257687&rft.externalDBID=n%2Fa&rft.externalDocID=A632900175 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-7007&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-7007&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-7007&client=summon |